Hansa Biopharma AB
Other OTCTotal Valuation
Hansa Biopharma AB carries a market capitalization of 369.01M, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 369.01M |
| Enterprise Value | 2.91B |
Share Statistics
Hansa Biopharma AB currently has 82.56M shares outstanding.
| Shares Outstanding | 82.56M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9.95, and the price-to-book ratio stands at -5.34.
| PE Ratio | N/A |
| PS Ratio | 9.95 |
| PB Ratio | -5.34 |
| P/TBV Ratio | -3.43 |
| P/FCF Ratio | -3.60 |
| P/OCF Ratio | -3.60 |
Enterprise Valuation
| EV / Sales | 14.79 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Hansa Biopharma AB maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -205.46, indicating conservative leverage, while an interest coverage ratio of -3.23 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.37 |
| Quick Ratio | 0.84 |
| Debt / Equity | -205.46 |
| Debt / EBITDA | -1.68 |
| Interest Coverage | -3.23 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -66.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 25.05 |
Taxes
| Income Tax | 4.14M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Hansa Biopharma AB's stock has gained approximately 35.0365% over the past 52 weeks. The 50-day moving average sits at 3.32, while the 200-day moving average is 3.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 35.0365% |
| 50-Day Moving Average | 3.32 |
| 200-Day Moving Average | 3.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hansa Biopharma AB generated 196.47M in revenue and converted that into -616.54M in net income, yielding earnings per share of -8.99. EBITDA reached -539.02M, while operating income came in at -539.02M.
| Revenue | 196.47M |
| Gross Profit | 133.08M |
| Operating Income | -539.02M |
| Pretax Income | -612.41M |
| Net Income | -616.54M |
| EBITDA | -539.02M |
| EBIT | -539.02M |
| Earnings Per Share (EPS) | -8.99 |
Balance Sheet
Hansa Biopharma AB holds 354.42M in cash and equivalents against 906.21M in total debt, resulting in a net debt position of 540.69M. Total book value stands at -441.06M, with working capital of 156.84M providing operational flexibility.
| Cash & Cash Equivalents | 354.42M |
| Total Debt | 906.21M |
| Net Debt | 540.69M |
| Equity (Book Value) | -441.06M |
| Book Value Per Share | -5.34 |
| Working Capital | 156.84M |
Cash Flow
Hansa Biopharma AB produced -542.67M in operating cash flow over the past twelve months.
| Operating Cash Flow | -542.67M |
| Capital Expenditures | N/A |
| Free Cash Flow | -542.67M |
| FCF Per Share | -7.92 |
Margins
Hansa Biopharma AB operates with a gross margin of 67.73, reflecting its pricing power and cost economics. The operating margin of -274.35 and net profit margin of -313.81 provide insight into operational efficiency.
| Gross Margin | 67.73 |
| Operating Margin | -274.35 |
| Pretax Margin | -311.70 |
| Profit Margin | -313.81 |
| EBITDA Margin | -274.35 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.96 |
| FCF Yield | -27.76 |
Scores
Hansa Biopharma AB posts an Altman Z-Score of -1.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.25 |